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Abstract
Background: Numerous genetic and genomic datasets related to complex diseases have been made available
during the last decade. It is now a great challenge to assess such heterogeneous datasets to prioritize disease
genes and perform follow up functional analysis and validation. Among complex disease studies, psychiatric
disorders such as major depressive disorder (MDD) are especially in need of robust integrative analysis because
these diseases are more complex than others, with weak genetic factors at various levels, including genetic
markers, transcription (gene expression), epigenetics (methylation), protein, pathways and networks.
Results: In this study, we proposed a comprehensive analysis framework at the systems level and demonstrated
it in MDD using a set of candidate genes that have recently been prioritized based on multiple lines of
evidence including association, linkage, gene expression (both human and animal studies), regulatory pathway,
and literature search. In the network analysis, we explored the topological characteristics of these genes in the
context of the human interactome and compared them with two other complex diseases. The network
topological features indicated that MDD is similar to schizophrenia compared to cancer. In the functional
a n a l y s i s ,w ep e r f o r m e dt h eg e n es e tenrichment analysis for both Gene Ontology categories and canonical
pathways. Moreover, we proposed a unique pathway crosstalk approach to examine the dynamic interactions
among biological pathways. Our pathway enrichment and crosstalk analyses revealed two unique pathway
interaction modules that were significantly enriched with MDD genes. These two modules are neuro-
transmission and immune system related, supporting the neuropathology hypothesis of MDD. Finally, we
constructed a MDD-specific subnetwork, which recruited novel candidate genes with association signals from a
major MDD GWAS dataset.
Conclusions: This study is the first systematic network and pathway analysis of candidate genes in MDD, providing
abundant important information about gene interaction and regulation in a major psychiatric disease. The results
suggest potential functional components underlying the molecular mechanisms of MDD and, thus, facilitate
generation of novel hypotheses in this disease. The systems biology based strategy in this study can be applied to
many other complex diseases.
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During the past decade, rapid advances in high through-
put technologies have helped investigators generate
numerous genetic and genomic datasets, aiming to
uncover disease causal genes and their actions in com-
plex diseases. These datasets are often heterogeneous
and multi-dimensional; thus, it is difficult to find consis-
tent genetic signals for the connection to the corre-
sponding disease. Specifically in psychiatric genetics,
there have been numerous datasets from different plat-
forms or sources such as association studies, including
genome-wide association studies (GWAS), genome-wide
linkage scans, microarray gene expression, and copy
number variation, among others. Analyses of these data-
sets have led to many exciting discoveries, including dis-
ease susceptibility genes or loci, providing important
insights into the underlying molecular mechanisms of
the diseases. However, the results based on single
domain data analysis are often inconsistent, with a very
low replication rate in psychiatric disorders [1,2]. It has
now been commonly accepted that psychiatric disorders,
such as schizophrenia and major depressive disorder
(MDD), have been caused by many genes, each of which
has a weak or moderate risk to the disease [3,4]. Thus, a
convergent analysis of multi-dimensional datasets to
prioritize disease candidate genes is urgently needed.
Such an approach may overcome the limitation of each
single data type and provide a systematic view of the
evidence at the genomic, transcriptomic, proteomic,
metabolomic, and regulatory levels [5,6].
Recently, pathway and network-assisted analyses of
genomic and transcriptomic datasets have been emer-
ging as powerful approaches to analyze disease genes
and their biological implications [7-11]. According to
the observation of “guilt by association”,g e n e sw i t h
similar functions have been demonstrated to interact
with each other more closely in the protein-protein
interaction (PPI) networks than those functionally unre-
lated genes [12]. Similarly, we have seen accumulating
evidence that complex diseases are caused by functional
related genes (e.g., in pathways or protein complex)
through their dynamic interaction and regulation rather
than action by single gene alone. Taken together, a sys-
tematic analysis and comparison of disease genes in the
PPI network would provide additional insights into the
diseases that otherwise could not be identified by single
gene or single marker analysis. It is important to note
that, although network-based analysis has been widely
applied in major complex diseases such as cancer, its
application in psychiatric diseases has been limited so
far.
MDD is a complex mental disorder with a lifetime
prevalence of 9-19% [13-15] and moderate heritability
(37-43%) [16]. Previous studies have suggested the invol-
vement of polygenic and mutifactorial features in the
pathology of MDD, as well as complex interactions
among genes (G×G) and environmental factors (G×E)
[17,18]. Recently, we have performed the first gene
prioritization using multi-dimensional evidence-based
datasets in MDD, including association, linkage, gene
expression (both human and animal studies), regulatory
pathway, and literature search (both human and animal
studies) [19]. A list of depression candidate genes
(which we named DEPgenes) with high reliability has
been generated based on this strategy [19]. However,
several characteristics remain unclear: the functional
relationships among these DEPgenes, how they interact
and regulate with each other, and how they act in the
MDD. Such investigations are warranted for a deeper
understanding of the molecular mechanisms of MDD
but require comprehensive analysis at the systems biol-
ogy level.
In this study, we first explored DEPgenes in the con-
text of the PPI network for their topological characteris-
tics and compared them with two representative
complex diseases: schizophrenia and cancer. We per-
formed the functional enrichment analyses using anno-
tations from both Gene Ontology (GO) [20] and
canonical pathways. More importantly, we examined
crosstalk among the significantly enriched pathways by
quantitatively measuring the shared protein components
between each pair of pathways. Finally, we constructed a
MDD-specific subnetwork using the DEPgenes and vali-
dated them using the association data from an indepen-
dent GWAS dataset for MDD. Our work demonstrated
a practical framework for complex disease candidate
gene analysis at the functional level, which can be
applied to other complex diseases.
Materials and methods
Depression candidate genes
We modified the scoring scheme in the gene prioritiza-
tion system proposed by Kao et al [19] and reprioritized
a list of 151 DEPgenes for MDD using the updated data
information. Briefly, several lines of evidence-based data-
sets were collected for MDD, including association stu-
dies, linkage scans, gene expression (both human and
animal studies), literature search (both human and ani-
mal studies), and biological regulatory pathways. A data-
set-specific score was assigned for each gene in each
data source, and all data types were combined by an
optimized weighting matrix to indicate the priority of a
gene’s association with MDD. The final gene list was
selected based on a set of previously implicated core
genes for MDD and validated by the GWAS dataset.
Detailed information of this gene prioritization
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number of genes we used here is slightly different from
that in Kao et al [19] due to the data and annotation
updates, but the two lists were very similar.
Other data sources and process
For the purpose of comparison, we collected schizo-
phrenia candidate genes and cancer genes. Schizophre-
nia is a severe psychiatric disorder and has been
suggested to share certain comorbidity with MDD
clinically and genetically [21]. We included this disor-
der here to represent other psychiatric disorders for
the purpose of comparison. We retrieved 160 schizo-
phrenia candidate genes prioritized in our recent work
using a similar multi-dimensional evidence-based strat-
egy [22]. Cancer has been the most studied among all
complex disease and is expected to have substantially
different pathological features from MDD. Thus, it
would be interesting to see how those genes act differ-
ently at the network and pathway levels. Cancer genes
were downloaded from the Cancer Gene Census data-
base [23] (CGC, July 2011).
The human PPI data was downloaded from the Pro-
tein Interaction Network Analysis (PINA) platform
(downloaded in March 2010) [24], which collected and
annotated data from six public PPI databases (MINT,
I n t A c t ,D I P ,B i o G R I D ,H P R D ,a n dM I P S / M P a c t ) .O n l y
proteins that could be successfully mapped to NCBI
protein-coding genes were included in our analysis (see
below). After removing self-interaction and duplicates,
the final network included a total of 10,377 nodes and
50,109 interactions.
The GWAS dataset for major depression (dbGaP
Study Accession: phs000020.v2.p1) was retrieved
through our approved access to dbGaP [25]. We devel-
oped a pipeline for quality controls (QC) to the dataset.
Detailed information can be found in our previous stu-
dies [19,26-28]. As a brief summary, there were 1,738
depression patients and 1,802 matched normal controls,
and 424,861 markers after QC, covering a total of
16,758 genes. This dataset was used to evaluate the
genes identified in this work.
To coordinate these heterozygous datasets in this
study, we downloaded several key annotation files from
the National Center for Biotechnology Information
(NCBI) [29] for the ease of integration. These included
the annotation files of Homo_sapiens.gene_info.zip, gen-
e_refseq_uniprotkb_collab.zip,a n dgene2refseq.zip (as of
November 24, 2010). DEPgenes, schizophrenia candidate
genes, cancer genes, PPI data, and GWAS data were all
mapped to human protein-coding genes from NCBI.
Those genes that could not be mapped appropriately
were discarded from the subsequent analysis.
Network topological properties
In network analysis, there are several key topological
indicators that have been defined to describe the beha-
viors or characteristics of the nodes in a network. The
most representative ones are degree, betweenness, and
shortest path. Degree is defined as the number of adja-
cent edges of a given node (protein) or the number of
neighbor nodes interacting with it. Betweenness of a
node is defined as the number of shortest paths going
through the node; shortest path measures the nearest
distance traveling from one node to another. We chose
to examine the distribution of degree and betweenness
of DEPgenes for exploration of their topological beha-
viors, and compared them with those of schizophrenia
candidate genes [22] and cancer genes [30].
Functional enrichment tests
To perform functional enrichment tests of the candidate
genes, we used WebGestalt [31] for Gene Ontology
(GO) term analysis and used the Ingenuity Pathway
Analysis (IPA) system [32] for both canonical pathways
and molecular networks. Although WebGestalt can per-
form enrichment tests for the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways [33], the IPA
system provides a more comprehensive pathway
resource based on manual collection and curation. The
rich information returned by IPA is also suitable for
pathway crosstalk analysis (see below), as it has more
molecules and their connections included. Briefly, Web-
Gestalt implements the hypergeometric test for the
enrichment of GO terms in the candidate genes, fol-
lowed by the correction of multiple testing using the
Benjamini & Hochberg (BH) method [34]. The IPA sys-
tem implements Fisher’s exact test to determine whether
a canonical pathway is enriched with genes of interest.
Furthermore, the network analysis in the IPA system
searches for significant molecular networks in a com-
mercial knowledge base, including integrative informa-
tion from literature, gene expression, and gene
annotation.
Pathway crosstalk
We performed pathway crosstalk analysis using the
pathways that were significantly enriched with DEPgenes
after multiple testing correction. Two pathways are con-
sidered to crosstalk if they share a proportion of DEP-
genes. We introduced two measurements to
computationally indicate the overlap of a pair of path-
ways: the Jaccard Coefficient JC =

A∩B


A∪B
 and the Over-
lap Coefficient OC =

A∩B

min(|A|,|B|)
,w h e r eA and B
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ways, respectively. To avoid non-specific inclusion of
crosstalk, we further implemented the following rules:
(1) only pathways with at least 5 DEPgenes were used;
(2) only pathways with adjusted P values < 0.01 were
used; and (3) two pathways in crosstalk were required to
share at least 3 DEPgenes. These criteria were intro-
duced to ensure that each of the pathways, as well as its
crosstalk pair, have not only statistical significance but
also a biologically meaningful number of genes, as some
pathways may be too small. Finally, we found many sig-
nificant pathways were identified by IPA; thus, they gen-
erated thousands of crosstalk events when all the
pathway combinations were compared. In practice, we
chose only those crosstalk events that had scores within
the top 10% of the score distribution. Although these
criteria were arbitrary, we found it worked efficiently to
balance an appropriate number of pathways and cross-
talk events.
Construction of MDD-specific subnetwork
To construct a MDD-specific subnetwork, we applied
the Steiner minimum tree algorithm that is implemen-
ted in our software framework GenRev [35] to the 151
DEPgenes. Solving the Steiner minimum tree algorithm
was proposed by Klein and Ravi [36], which can be used
for constructing a connected subnetwork given a list of
query nodes. In our case, the query nodes are those
encoded by DEPgenes, and the whole network is the
human interactome extracted from the PINA database
(see above). This algorithm aims to connect a maximum
proportion of the query nodes. To accomplish this, addi-
tional nodes in the network, but not in the query list,
w o u l db er e c r u i t e di no r d e rt om a k et h et a r g e ts u b n e t -
work interconnected, while the algorithm is optimized
towards a minimum list of the additional nodes. GenRev
is a recently developed software tool which implements
the Steiner minimum tree algorithm, as well as two
other popular algorithms for subnetwork construction.
It has been successfully applied in our previous work
[6,22,37]. In the work discussed here, we used it for
DEPgenes to construct MDD-specific subnetwork.
Results
Network topological properties of depression genes
We collected 151 major depressive disorder candidate
genes (DEPgenes). Among them, 134 had protein inter-
action annotations in the human interactome. Figure 1
shows the degree distribution. The average degree of
these proteins was 18.55, and their median degree value
was 6. As a comparison, the average degree was 14.75
(median value 6) for the schizophrenia candidate genes
(131 of the 160 genes mapped onto the human interac-
tome) and 25.53 (median value 12) for the cancer genes
(353 of the 459 genes mapped onto the interactome).
Overall, although DEPgenes on average had a higher
degree value than schizophrenia genes, their degree dis-
tribution is similar to that of schizophrenia genes, and
statistical tests indicated no significant difference (Wil-
coxon test, P = 0.53). However, we observed different
degree distributions between DEPgenes and cancer
genes, and statistical tests indicated that DEPgenes had
significantly lower degrees than cancer genes (P =1 . 9 3
×1 0
-5). Specifically, cancer genes were found more fre-
quently in the degree bins 18-32 and 32-40 (Figure 1).
For the measurement of betweenness, the average
value was 5.02 × 10
4 for DEPgenes, 4.01 × 10
4 for the
schizophrenia genes, and 5.61 × 10
4 f o rc a n c e rg e n e s ,
while their median values were 5.12 × 10
3,3 . 5 4×1 0
3,
and 1.02 × 10
4, respectively. Similar to the measurement
of degree, there was no significant difference in the
betweenness values between the MDD and schizophre-
nia candidate genes (P = 0.21), but cancer genes had sig-
nificantly larger betweenness values than DEPgenes (P =
0.03). These results indicated that the candidate genes
for the two major psychiatric disorders, MDD and schi-
zophrenia, shared similar topological features in the
human interactome, while both had substantially differ-
ent features when compared to cancer genes.
Gene Ontology enrichment analysis by WebGestalt
To explore whether DEPgenes share specific functional
features, we performed GO enrichment analysis using
WebGestalt (version 2.0). We found that many neurode-
velopment related functions and biological processes
were significantly enriched in DEPgenes, regardless of
GO terms categories (BP: biological process; MF: mole-
cular function; and CC: cellular component) (Table 1).
The most significant terms in each of these three GO
categories are: synaptic transmission in biological pro-
cess (PBH =1 . 1 8×1 0
-34), G-protein coupled amine
receptor activity in molecular function (PBH = 7.18 × 10
-
19), and neuron projection in cellular component (PBH =
3.91 × 10
-20). Other enriched GO terms of interest
include transmission of nerve impulse, neurological pro-
cess, cell communication, dopamine binding, extracellu-
lar ligand-gated ion channel activity, ligand-gated
channel activity, axon, and dendrite.
Pathway enrichment by Ingenuity Pathway Analysis
We then examined whether DEPgenes are enriched in
canonical pathways by performing Fisher’s exact test in
the IPA system. Table 2 shows the 12 most significantly
enriched pathways. Remarkably, most of them are
related to the neurotransmission system, supporting the
neuropathology hypothesis of MDD (Table 2). Among
them, we highlighted serotonin receptor signaling, dopa-
mine receptor signaling, PXR/RXR activation,
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CREB signaling in neurons and tryptophan metabolism.
This result is consistent with prior knowledge of MDD
[38,39], providing further evidence of the neuro-related
processes in this disorder.
Crosstalk among significantly enriched pathways
Since many genes and pathways might be involved in
MDD, to more deeply understand how these pathways
are related, we performed a pathway crosstalk analysis.
We first selected the significantly enriched pathways
from the IPA results. Specifically, we selected those
pathways having PBH <0 . 0 1a n d≥ 5D E P g e n e s .T h e r e
were 71 pathways that met these criteria. Among them,
69 pathways shared at least 3 genes with other path-
ways. A total of 571 edges (links) connected between
any two of these pathways, and these edges were ranked
according to the average scores of the Jaccard Coeffi-
cient and the Overlap Coefficient (see the Materials and
methods section). We selected the top 10% edges, which
resulted in 57 pairs of pathway crosstalk, and con-
structed the pathway crosstalk network for MDD. This
pathway crosstalk was the first of its kind in MDD.
Graphical presentation of the selected pathway cross-
talk revealed two self-clustered modules, as well as small
but strongly-linked pathway pairs. As shown in Figure 2,
t h et w ol a r g em o d u l e sa r ed o m i n a t e db yn e u r o - r e l a t e d
signal transduction and immune related pathways,
respectively. The neuro-related signal transduction mod-
ule consists of the calcium signaling pathway, synaptic
long term potentiation, CREB signaling in neurons, axo-
nal guidance signaling, and others. These pathways have
Figure 1 Comparison of degree distribution of major depressive disorder (MDD), schizophrenia (SCZ), and cancer genes. The disease
genes were grouped by their degree into degree bins. Here, degree was measure by the number of interactors for each disease gene in the
human interactome. The top panel shows the histogram degree distribution, and the bottom panel shows the curve degree distribution. In the
bottom panel, each vertical line represents the median value of the degrees in each disease category. Note that MDD and SCZ candidate genes
had the same median value of degrees so that their vertical lines could not be distinguished.
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chiatric disorders that share comorbidity with MDD
[5,40,41].
The second large pathway crosstalk module mainly
consisted of immune-related pathways, such as IL-6 sig-
naling and LXR/RXR activation (Figure 2). This strongly
supports recent discoveries of immunity and inflamma-
tion related processes in psychiatric disorders [42,43],
including MDD [44]. Many genes that drove the cross-
talk in the figure were also found to function in both
neuro- and immune-related processes like APOE [45],
TNF [46], and IL6 [47].
Molecular subnetwork
A total of 8 significant molecular networks were identi-
fied by Fisher’s exact test in the IPA system with addi-
tional criteria specifying that a pathway’ss c o r ew a sa t
least 10 and each pathway had at least 10 DEPgenes.
Here, score was transformed from -logP, where P is cal-
culated by the Fisher’s exact test. Figure 3 showed the
two most significant networks, in which DEPgenes were
Table 1 Gene Ontology (GO) terms enriched with module genes (GO level ≥ 4)
GO terms Observed* PP BH
$
Biological process
GO:0007268: synaptic transmission 45 7.18 × 10
-38 1.18 × 10
-34
GO:0007267: cell-cell signaling 56 8.78 × 10
-37 7.21 × 10
-34
GO:0019226: transmission of nerve impulse 46 2.84 × 10
-36 1.55 × 10
-33
GO:0044057: regulation of system process 36 1.23 × 10
-29 2.89 × 10
-27
GO:0051239: regulation of multicellular organismal process 55 1.07 × 10
-29 2.89 × 10
-27
GO:0050877: neurological system process 59 4.72 × 10
-26 9.69 × 10
-24
GO:0007154: cell communication 103 6.14 × 10
-26 1.12 × 10
-23
Molecular function
GO:0008227: G-protein coupled amine receptor activity 15 5.13 × 10
-21 7.18 × 10
-19
GO:0035240: dopamine binding 7 2.25 × 10
-13 1.58 × 10
-11
GO:0005230: extracellular ligand-gated ion channel activity 12 4.17 × 10
-12 2.34 × 10
-10
GO:0004888: transmembrane receptor activity 40 6.55 × 10
-12 2.78 × 10
-10
GO:0005102: receptor binding 31 9.87 × 10
-11 3.07 × 10
-9
GO:0022834: ligand-gated channel activity 13 2.46 × 10
-10 5.74 × 10
-9
Cellular component
GO:0043005: neuron projection 30 2.43 × 10
-22 3.91 × 10
-20
GO:0044459: plasma membrane part 61 3.12 × 10
-20 2.51 × 10
-18
GO:0000267: cell fraction 45 1.45 × 10
-19 7.78 × 10
-18
GO:0005887: integral to plasma membrane 47 5.84 × 10
-19 2.35 × 10
-17
GO:0031226: intrinsic to plasma membrane 47 1.27 × 10
-18 4.09 × 10
-17
GO:0042995: cell projection 35 5.50 × 10
-18 1.48 × 10
-16
GO:0005886: plasma membrane 80 1.64 × 10
-17 3.77 × 10
-16
GO:0030424: axon 18 1.15 × 10
-15 2.31 × 10
-14
GO:0030425: dendrite 17 2.76 × 10
-14 4.94 × 10
-13
GO:0005626: insoluble fraction 32 7.11 × 10
-13 1.14 × 10
-11
*Number of the observed DEPgenes in the category.
$P values were adjusted by Benjamini & Hochberg (BH) method [34].
Table 2 Canonical pathways enriched with module genes
by Ingenuity Pathway Analysis (IPA) (PBH <1 0
-6)
Ingenuity canonical pathways Observed* PBH
$
cAMP-mediated signaling 23 6.31 × 10
-16
G-protein coupled receptor signaling 31 5.01 × 10
-15
Serotonin receptor signaling 12 6.31 × 10
-15
Corticotropin releasing hormone signaling 14 7.94 × 10
-11
Dopamine receptor signaling 11 3.80 × 10
-9
Glucocorticoid receptor signaling 17 1.35 × 10
-8
PXR/RXR activation 10 2.29 × 10
-8
Amyotrophic lateral sclerosis signaling 11 5.89 × 10
-8
Neuropathic pain signaling on dorsal horn
neurons
11 5.89 × 10
-8
Relaxin signaling 12 1.02 × 10
-7
CREB signaling in neurons 13 1.62 × 10
-7
Tryptophan metabolism 11 6.61 × 10
-7
*Number of the observed DEPgenes in the category.
$P values were adjusted by Benjamini & Hochberg (BH) method [34].
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observed 18 DEPgenes, and the top functions of this
network included energy production, drug metabolism,
and small molecule biochemistry. The second network,
which consisted of 18 DEPgenes too, was enriched with
the functions of genetic disorder, neurological disease,
and psychological disorders. On the molecular level, we
observed a group of serotonin receptors and G-proteins
(Figure 3), further supporting the involvement of neuro-
logical signaling in major depressive disorder.
MDD-specific subnetwork
Among the 151 DEPgenes, 134 were found to have PPI
annotations in the human interactome. Using our
recently developed subnetwork extraction tool GenRev,
we successfully constructed a MDD-specific subnetwork.
The subnetwork contained 130 DEPgenes and 62 addi-
tional genes that were recruited via the subnetwork con-
struction algorithm (Steiner minimum tree algorithm
[36]) (Figure 4). To evaluate the genes identified in the
subnetwork, we compared their P values in a GWAS
dataset for MDD (see the Materials and methods sec-
tion). Among the 16,758 genes in the MDD GWAS
dataset, we had 122 DEPgenes in the subnetwork, 56
non-DEPgenes in the subnetwork (we named them sub-
network’s recruited genes), and remaining 16,580 genes
outside of the subnetwork. For each gene, we assigned a
gene-wise P value based on the SNP that had the
Figure 2 Pathway crosstalk and functional map of DEPgenes (major depressive disorder genes). In this figure, each node represents a
significant pathway, and each edge represents a pathway crosstalk, i.e., a significant overlap of the component genes between two linked
pathways. The color of each node is approximately proportional to the adjusted P (PBH) value of the corresponding pathway in the pathway
enrichment analysis by Ingenuity Pathway Analysis (IPA). Darker color indicates lower PBH value. The size of each node is approximately
proportional to the number of DEPgenes found in the corresponding pathway. The width of each edge is approximately proportional to the
overlap score of the related pathways (see Materials and methods).
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gene region [4,26]. When we separated gene-wise P
values into four bins (<0.001, 0.001-0.01, 0.01-0.05, and
≥0.05), we found both the DEPgenes and the newly
recruited genes in the subnetwork were more frequent
in the small P value bins (<0.001, 0.001-0.01, 0.01-0.05)
than other genes (Figure 5). Furthermore, DEPgenes
tended to have smaller gene-wise P values than the
newly recruited genes, supporting that subnetwork ana-
lysis could identify potential disease genes that would
otherwise unlikely be detected by traditional singe gene
or single marker associations t u d i e s .W h e nu s i n gc u t o f f
value 0.05 to separate the genes into three gene sets (i.
e., nominally significant genes were defined as those
with gene-wise P value < 0.05), we found that the DEP-
genes in the subnetwork had a significantly larger pro-
portion of nominally significant genes in the GWAS
dataset (Fisher’s exact test, P = 4.13 × 10
-4) compared to
the remaining genes. The recruited genes in the subnet-
work were found to have a similar trend of larger pro-
portion of nominally significant genes than remaining
genes, but this difference was not significant (P = 0.10).
Of note, when comparing the genes in the MDD-speci-
fic subnetwork (122+56 = 178 genes) with those outside
of the network (16,580 genes), the subnetwork genes
had significantly more nominally significant genes (P =
1.81 × 10
-4).
Discussion
Although there have been numerous reports of suscept-
ibility genes or loci to psychiatric disorders such as
major depressive disorder and schizophrenia, no disease
causal genes have been confirmed [48-50]. One impor-
tant task now is to reduce the data noise and prioritize
the candidate genes from multiple dimensional genetic
and genomic datasets that have been made available
during the last decade and then explore their functional
relationships for further validation. To our knowledge,
this is the first systematic network and pathway analysis
for MDD using candidate genes prioritized from com-
prehensive evidence-based data sources. By overlaying
the MDD candidate genes in the context of the human
interactome, we examined the topological characteristics
of these genes by comparing them with those of schizo-
phrenia and cancer candidate genes. We further per-
formed pathway enrichment analysis to better
understand the biological implications of these genes in
the context of the regulatory system. Building on our
observation of the large number of pathways enriched
with DEPgenes, we developed novel approaches to
Figure 3 The top two molecular networks identified by Ingenuity Pathway Analysis (IPA). (A) The most significant molecular network by
IPA pathway enrichment analysis. (B) The second most significant molecular network. Color of each node indicates the score of each DEPgene
calculated by multiple lines of genetic evidence, as described in Kao et al [19].
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and regulation could be explored, thus providing us new
insights into the interpretation of the underlying mole-
cular mechanisms in MDD.
Our network topological analysis revealed that DEP-
genes showed similar topological characteristics to schi-
zophrenia, supporting previous reports that depression
and schizophrenia might share comorbidity both clini-
cally and genetically [21]. For example, clinical symptoms
such as psychosis and neuro-cognitive impairments have
been observed in both depression and schizophrenia
patients [21], and shared genetic variance has been
reported between major depression and schizophrenia
[51,52]. Although similar network topological features
a r ee x p e c t e db ym a n yi n v e s t i g a t o r s ,o u rs t u d yw a st h e
first to confirm, and provided further evidence, that the
topological features of depression genes are different
from cancer genes. It is worth noting that, although
depression and schizophrenia genes had similar degree
distributions (Figure 1), depression genes had moderately
stronger connectivity and betweenness than schizophre-
nia genes.
Of significance, our pathway crosstalk analysis revealed
two large clustered modules, both of which had impor-
tant implications to MDD (Figure 2). The first cluster
included 17 pathways, and it was dominated by neuro-
signaling pathways. Among these pathways, neuropathic
pain signaling in dorsal horn neurons (PBH =5 . 8 9×1 0
-
8), CREB signaling in neurons (PBH =1 . 6 2×1 0
-7), synap-
tic long term potentiation (PBH = 6.17 × 10
-5), and axonal
Figure 4 Major depressive disorder (MDD) specific protein-protein interaction subnetwork. Round nodes are DEPgenes (MDD candidate
genes) and triangular nodes are additional genes recruited by subnetwork construction. The darkness of node color is approximately
proportional to the integrative evidence score of each DEPgene, as described in Kao et al [19].
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-4) are involved in
neuron/brain tissues and have been reported to be
involved in MDD [53,54]. Our further examination of the
genes contributing to the crosstalk revealed that the most
frequently shared genes in this cluster were PRKACA
(functioning in n = 15 pathways in this cluster), GNAS (n
=1 4 ) ,GNB3 (n = 13), ADCY7 (n = 10), GNAL (n = 9),
AKT1 (n = 9), CREB1 (n = 8), CAMK2A (n = 6), GRIN2B
(n = 5), GRIN2A (n = 5), and GRIN1 (n = 5), among
others.
The second cluster is primarily related to immunity
and inflammation, including the IL-6 signaling pathway
(PBH =6 . 1 7×1 0
-3), differential regulation of cytokine
production in macrophages and T helper cells by IL-
17A and IL-17F (PBH =8 . 1 3×1 0
-6), and LXR/RXR acti-
vation (PBH =4 . 5 7×1 0
-4). For example, the LXR/RXR
pathway may play a role in the prevention of pro-
grammed cell death and a role in immune responses to
inhibit inflammatory gene expression [55]. The most
frequently shared genes in this cluster included TNF
(functioning in n = 14 pathways), IL6 (n = 13), IL1B
(n = 13), IL10 (n = 9), CCL2 (n = 8), NGFR (n = 7), and
AKT1 (n = 7), among others. These genes further sup-
port the observation that immune- and inflammation-
related functions are involved in this cluster. During
recent years, evidence of immune and inflammation sys-
tems in psychiatric disorders has accumulated quickly
[3,4,56].
In addition to the two major clusters, there are other
crosstalk pairs that are noteworthy. The most interesting
one is the pathway pair of cAMP-mediated signaling
and G-protein coupled receptor signaling. The evidence
linking these two pathways is strong, as its edge had a
score 0.87. Moreover, these two pathways had the most
significant enrichment test P values (6.31 × 10
-16 and
5.01 × 10
-15, respectively) in the IPA canonical pathway
analysis (Table 2). The interaction between these two
pathways involved 23 DEPgenes, including several sero-
tonin receptor genes like HTR1A, HTR1B,a n dHTR5A.
The cAMP-mediated signaling and G-protein coupled
receptor signaling pathways have long been studied for
their roles in the nervous system. Of note, there were
Figure 5 Comparison of the distribution of GWAS P values in three gene sets: DEPgenes in the MDD-specific subnetwork, non-
DEPgenes recruited in the MDD-specific subnetwork, and other genes examined in the GWAS dataset. X-axis is the gene-wise P value
grouped into four bins, and Y-axis is the proportion of genes in the corresponding P value bin.
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ways and other pathways that were enriched with the
DEPgenes. Those pathway crosstalk connections were
not shown in Figure 2 because they did not meet our
s t r i n g e n tc r i t e r i af o rp a t h w a yi n c l u s i o n( a tl e a s t3D E P -
genes shared between the pair of pathways or not within
the top 10% crosstalk score, see the Materials and meth-
ods section). One example is the link between the
cAMP-mediated signaling pathway and the serotonin
receptor signaling, both of which were significantly
enriched with DEPgenes, but their crosstalk score fell
outside of the top 10% in the score distribution.
Our aim of the depression-specific subnetwork con-
struction was to explore functional interactions of DEP-
genes in a local protein-protein interaction environment.
Our follow-up evaluation of the disease association of
both DEPgenes and the additionally recruited genes
using a major GWAS dataset for depression found that
these genes tended to have small P-values (i.e., at the
nominal significance level). Since the GWAS data we
used here was an independent dataset, and GWAS was
designed to be hypothesis free in genome-wide associa-
tion studies, our survey of MDD-specific subnetwork
genes demonstrated that this approach is efficient to
find a set of genes that are both functionally interactive
and enriched with the association signals of the corre-
sponding disease. Therefore, this approach is not only
promising to find novel disease candidate genes for
future validation but also useful to study the disease at
the systems biology level.
This work has a few limitations. First, our DEPgenes
and the follow up pathway/network analyses were con-
ducted based on computational strategies. Although
informative, this approach generally requires extensive
experimental validation. Thus, although we validated
subnetwork genes at the genome-wide level using the
GWAS dataset, further validation of specific novel genes
using more samples is urgently needed. Second, the
pathway crosstalk analysis was based on the scores mea-
sured by Jaccard Coefficient (JC) and Overlap Coeffi-
cient (OC). In this study, we selected the pathway pairs
empirically, that is, those ranked in the top 10%. P
values from a statistic test would be better applied to
select significant crosstalk. We did not apply this
method because the Ingenuity Pathway Analysis system
is a commercial software tool, and the information
needed to conduct such a statistic test is not publically
available. Accordingly, we could only use the limited
information for pathway crosstalk analysis. Third, the
MDD-specific subnetwork was built on available human
interactome data. Although the number and quality of
protein interactions has recently improved greatly, the
human interactome is still incomplete with many false
positives [24]. Additionally, subnetwork extraction relies
on specific algorithms and corresponding parameters.
Several algorithms exist for subnetwork extraction. In
this study, we applied the Steiner minimum tree algo-
rithm, which can effectively reduce unrelated nodes
(genes) to be included, but it may also miss some
important functional links. Our analysis, along with our
recent application of this algorithm in other complex
diseases (schizophrenia [5,57], hepatocellular carcinoma
[37], and epilepsy [6]), has demonstrated this strategy is
practical and could provide valuable information of the
interactions among DEPgenes.
Conclusions
We developed a systems biology framework for
advanced and functional analyses of major depressive
disorder candidate genes. The network topological ana-
lysis revealed similar network characteristics between
depression and schizophrenia, but network characteris-
tics of both depression and schizophrenia differed from
cancer, consistent with previous clinical and genetic stu-
dies. However, the depression genes interacted moder-
ately stronger than schizophrenia genes in the context
of the protein-protein interaction network. Our pathway
enrichment tests followed by pathway crosstalk analysis
revealed that neurotransmission and immune systems
might play key roles in the etiology of depression,
assuming that our evidence-based DEPgenes were repre-
sentative of depression. Notably, we found two major
functional clusters in the pathway crosstalk network.
We further constructed a depression-specific subnet-
work, in which additional candidate genes were identi-
fied with enriched association signals using the
depression GWAS dataset. These findings present a
wealth of information for future validation. The frame-
work we presented in this work can be applied to many
other complex diseases, such as addiction and bipolar
disorder.
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